 BURLINGAME, Calif., Dec. 14, 2020 GLOBE NEWSWIRE -- ALX Oncology Holdings Inc. ALX Oncology Nasdaq: ALXO, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the closing of its previously announced underwritten public offering of 2,737,000 shares of its common stock, which includes the exercise in full of the underwriters option to purchase 357,000 additional shares of its common stock, at a price to the public of 76.00 per share. The aggregate gross proceeds to ALX Oncology from the offering were approximately 208.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by ALX Oncology. 